Sat.Sep 18, 2021

World Pharmacists Day 2021 Celebration

Pharma Mirror

25th September is celebrated as world pharmacists day, and it brings a new theme every year. The main motive behind this celebration is to give an excellent message to improve people’s health worldwide. And also, create an acceptance and encourage the role of a pharmacist in health.

82

Our Generic Drug Supply Is Sick

NY Times

Competition for market share at rock-bottom prices has led to shortages, price-spikes, allegations of price-fixing, and substandard and even dangerous practices.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Munich Clinical Trials Summit a Virtual Success! Technology Pushed to its Limits

Imperical Blog

Right at the start of the Covid pandemic last March, my colleague Dan McDonald and I were in Germany at the Munich OECT conference. Like an awkward tingle of electricity, there was an awareness that things might be about to change.

Personalis Receives New VA MVP Task Order and Record Quarterly Orders From Oncology Customers; Reconfirms Total Revenue Outlook for 2021 with Further Accelerated Oncology Growth

BioTech 365

Personalis Receives New VA MVP Task Order and Record Quarterly Orders From Oncology Customers; Reconfirms Total Revenue Outlook for 2021 with Further Accelerated Oncology Growth Personalis Receives New VA MVP Task Order and Record Quarterly Orders From Oncology Customers; Reconfirms … Continue reading → Business Wire

52

Portuguese initiative wins FIP Pharmacy Practice Improvement Award

Pharma Mirror

The Hague, A freephone service created by a pharmacy COVID-19 “crisis cabinet” to maintain care and help ensure safety of citizens and pharmacy teams following a declaration of a state of emergency is the winner of the International Pharmaceutical Federation (FIP) Pharmacy Practice Improvement Award 2021.

IMFINZI Plus Chemotherapy Tripled Patient Survival at Three Years in the CASPIAN Phase III Trial in Extensive-Stage Small Cell Lung Cancer

BioTech 365

IMFINZI Plus Chemotherapy Tripled Patient Survival at Three Years in the CASPIAN Phase III Trial in Extensive-Stage Small Cell Lung Cancer IMFINZI Plus Chemotherapy Tripled Patient Survival at Three Years in the CASPIAN Phase III Trial in Extensive-Stage Small Cell … Continue reading → Business Wire

Adjuvant immunotherapy prolongs recurrence-free survival in resected stage II B/C melanoma

Scienmag

Lugano, Switzerland, 18 September 2021 – The first randomised phase III clinical trial in stage II melanoma has shown a 35% reduction in the risk of recurrence with adjuvant pembrolizumab compared with placebo.

More Trending

Immunotherapy drug benefits patients with high-risk local melanomas

Scienmag

PITTSBURGH, Sept. 18, 2021 – An immunotherapy called pembrolizumab reduced cancer recurrence after surgery in patients with stage IIb and IIc melanoma, according to the results of an international, randomized phase III clinical trial led by UPMC Hillman Cancer Center.

Exelixis Announces Detailed Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer Presented at ESMO 2021

BioTech 365

Exelixis Announces Detailed Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer Presented at ESMO 2021 Exelixis Announces Detailed Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with Metastatic Castration-Resistant … Continue reading → Business Wire

Immunotherapy prolongs survival in recurrent, persistent or metastatic cervical cancer

Scienmag

Lugano, Switzerland, 18 September 2021 – The addition of immunotherapy to standard first-line treatment extends survival by eight months for patients with recurrent, persistent or metastatic cervical cancer, according to late breaking results from the KEYNOTE-826 study presented at the ESMO Congress 2021. (1)

ENHERTU® Demonstrated Robust and Durable Tumor Response of 54.9% in Patients with HER2 Mutant Metastatic Non-Small Cell Lung Cancer

BioTech 365

ENHERTU® Demonstrated Robust and Durable Tumor Response of 54.9% in Patients with HER2 Mutant Metastatic Non-Small Cell Lung Cancer ENHERTU® Demonstrated Robust and Durable Tumor Response of 54.9%

52

Catalent Signs Commercial Supply Agreement with Phathom

Pharma Mirror

SOMERSET, N.J.

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated robust and durable tumor response of 54.9% in patients with HER2-mutant metastatic non-small cell lung cancer

BioTech 365

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated robust and durable tumor response of 54.9% in patients with HER2-mutant metastatic non-small cell lung cancer ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated robust and durable tumor response of 54.9%

52

Pharmapack Report 2021

Pharma Mirror

Paris, Ahead of the first Pharmapack Europe to be held in nearly 18-months, Informa has released the results of its global drug delivery and packaging survey, with the USA once again leading ‘drug delivery and device innovation’, but lagging behind all major European nations on sustainability.

Spectrum Pharmaceuticals Presents Late Breaker Oral Presentation of Poziotinib Data in First-Line NSCLC Patients with HER2 Exon 20 Insertion Mutations at ESMO Congress 2021

BioTech 365

Spectrum Pharmaceuticals Presents Late Breaker Oral Presentation of Poziotinib Data in First-Line NSCLC Patients with HER2 Exon 20 Insertion Mutations at ESMO Congress 2021 Spectrum Pharmaceuticals Presents Late Breaker Oral Presentation of Poziotinib Data in First-Line NSCLC Patients with HER2 … Continue reading → Business Wire

52

Which pharmaceutical companies have the most SPCs in Finland?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Finland. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Finland?

80

ENHERTU® Reduced the Risk of Disease Progression or Death by 72% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer

BioTech 365

ENHERTU® Reduced the Risk of Disease Progression or Death by 72% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer ENHERTU® Reduced the Risk of Disease Progression or Death by 72% Versus Trastuzumab Emtansine (T-DM1) in Patients … Continue reading → Business Wire

52

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Death by One-Third Versus Chemotherapy With or Without Bevacizumab as First-Line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer

BioTech 365

52

ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease progression or death by 72% vs. trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer

BioTech 365

52

Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Superior Recurrence-Free Survival (RFS) in Patients With Resected High-Risk Stage II Melanoma Compared to Placebo in the Adjuvant Setting

BioTech 365

52

 Celltrion’s monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59) becomes the first authorized COVID-19 treatment approved from the Korean Ministry of Food and Drug Safety (MFDS)

BioTech 365

#news #biotech Yeast and bacteria together biosynthesize plant hormones for weed control

BioTech 365

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Yeast and bacteria together biosynthesize plant hormones for weed control.Plants regulate their growth and development using hormones, including a group called strigolactones that prevent excessive budding and … Continue reading → #news